Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-5-24
pubmed:abstractText
CBFbeta-SMMHC is expressed in 8% of acute myeloid leukemias and inhibits AML1/RUNX1. In this study, murine marrow or human CD34(+) cells were transduced with retroviral or lentiviral vectors expressing CBFbeta-SMMHC or two mutant variants. CBFbeta-SMMHC reduced murine or human myeloid cell proliferation three- to four-fold in liquid culture relative to empty vector-transduced cells, during a period when vector-transduced cells accumulated five-fold and human cells 20-fold. CBFbeta-SMMHC decreased the formation of myeloid, but not erythroid, colonies two- to four-fold, and myeloid colonies expressing CBFbeta-SMMHC were markedly reduced in size. However, CBFbeta-SMMHC did not slow differentiation to granulocytes or monocytes. Neither CBFbeta-SMMHC(Delta2-11), which does not bind AML1, nor CBFbeta-SMMHC(DeltaACD), which does not multimerize or efficiently bind corepressors, slowed proliferation or reduced myeloid colonies. CBFbeta-SMMHC increased the G1/S ratio 1.4-fold. AML1 had an effect opposite to CBFbeta-SMMHC, stimulating proliferation of murine myeloid progenitors 2.0-fold in liquid culture. Thus, CBFbeta-SMMHC directly inhibits the proliferation of normal myeloid progenitors via inhibition of AML1 and dependent upon the integrity of its assembly competence domain. These findings support the development of therapeutics that target the ability of CBFbeta-SMMHC to interact with AML1 or to multimerize via its assembly competence domain.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0887-6924
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
921-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:15815715-Acute Disease, pubmed-meshheading:15815715-Animals, pubmed-meshheading:15815715-Cell Differentiation, pubmed-meshheading:15815715-Cell Division, pubmed-meshheading:15815715-Core Binding Factor Alpha 2 Subunit, pubmed-meshheading:15815715-DNA-Binding Proteins, pubmed-meshheading:15815715-Female, pubmed-meshheading:15815715-Fetal Blood, pubmed-meshheading:15815715-Gene Therapy, pubmed-meshheading:15815715-Hematopoietic Stem Cells, pubmed-meshheading:15815715-Humans, pubmed-meshheading:15815715-Lentivirus, pubmed-meshheading:15815715-Leukemia, Myeloid, pubmed-meshheading:15815715-Mice, pubmed-meshheading:15815715-Mice, Inbred C57BL, pubmed-meshheading:15815715-Oncogene Proteins, Fusion, pubmed-meshheading:15815715-Proto-Oncogene Proteins, pubmed-meshheading:15815715-Retroviridae, pubmed-meshheading:15815715-Transcription Factors, pubmed-meshheading:15815715-Transduction, Genetic
pubmed:year
2005
pubmed:articleTitle
CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors.
pubmed:affiliation
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural